Skip Navigation LinksHome > February 2010 - Volume 16 - Issue 2 > Fontolizumab in moderate to severe Crohn's disease: A phase...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21038
Original Clinical Articles

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

Reinisch, Walter MD1,*; de Villiers, Williem MD, PhD2; Bene, László MD3; Simon, László MD4; Rácz, István MD5; Katz, Seymour MD6; Altorjay, István MD7; Feagan, Brian MD8; Riff, Dennis MD9; Bernstein, Charles N. MD10; Hommes, Daniel MD11; Rutgeerts, Paul MD, PhD12; Cortot, Antoine MD13; Gaspari, Michael MD14; Cheng, May BA15; Pearce, Tillman MD15; Sands, Bruce E. MD16

Collapse Box

Abstract

Background:: The safety and efficacy of fontolizumab, a humanized anti‐interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms.

Methods:: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels.

Results:: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%–38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C‐reactive protein levels. The overall frequency of adverse events was similar in all groups (58%–75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab.

Conclusions:: Although a strong clinical response to fontolizumab was not observed, significant decreases in C‐reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted. Inflamm Bowel Dis 2009

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.